Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

119 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
S-1360 Shionogi-GlaxoSmithKline.
Billich A. Billich A. Curr Opin Investig Drugs. 2003 Feb;4(2):206-9. Curr Opin Investig Drugs. 2003. PMID: 12669383 Review.
Shionogi and GlaxoSmithKline, as the joint venture company Shionogi-GlaxoSmithKline Pharmaceuticals, is developing S-1360, an HIV integrase inhibitor as a potential treatment for HIV infection. ...
Shionogi and GlaxoSmithKline, as the joint venture company Shionogi-GlaxoSmithKline Pharmaceuticals, is developing S-1360, an HIV integrase …
Pleconaril Sanofi Synthélabo/ViroPharma.
Billich A. Billich A. Curr Opin Investig Drugs. 2000 Nov;1(3):303-7. Curr Opin Investig Drugs. 2000. PMID: 11249712 Review.
A number of phase III clinical trials have been completed, and several others are ongoing [319499], [343187], [346302], [359231]. ...In July 2000, Salomon Smith Barney predicted a launch date of 2002 [387350]. In October 1999, Lehman Brothers predicted a 70%
A number of phase III clinical trials have been completed, and several others are ongoing [319499], [343187], [346302], [359231]. ...
Technology evaluation: FluMist, University of Michigan.
Billich A. Billich A. Curr Opin Mol Ther. 2000 Jun;2(3):340-4. Curr Opin Mol Ther. 2000. PMID: 11249630 Review.
GS-4104 Gilead Sciences Inc.
Billich A. Billich A. IDrugs. 1998 May;1(1):122-8. IDrugs. 1998. PMID: 18465516
Gilead and Roche are codeveloping GS-4104, a neuraminidase inhibitor, for the potential treatment and prevention of influenza virus infections, type A and type B. ...The trials involve over 1500 patients, who will receive either GS-4104 or placebo for 6 weeks, as …
Gilead and Roche are codeveloping GS-4104, a neuraminidase inhibitor, for the potential treatment and prevention of influenza virus i …
Amprenavir (Vertex Pharmaceuticals Inc).
Billich A. Billich A. IDrugs. 1999 May;2(5):466-82. IDrugs. 1999. PMID: 16155850
Amprenavir is a small molecule with significant aqueous solubility designed to combine antiviral potency with good oral bioavailability. ...Amprenavir selects for a unique mutation in the HIV-1 protease gene in vitro, and shows no or limited cross-resistance to othe …
Amprenavir is a small molecule with significant aqueous solubility designed to combine antiviral potency with good oral bioavailabili …
Entecavir (Bristol-Myers Squibb).
Billich A. Billich A. Curr Opin Investig Drugs. 2001 May;2(5):617-21. Curr Opin Investig Drugs. 2001. PMID: 11569933 Review.
Bristol-Myers Squibb (BMS) is developing entecavir, a viral replication inhibitor, for the potential treatment of hepatitis B virus (HBV) infection [220240]. ...The triphosphate form is a potent HBV polymerase inhibitor in both woodchuck and duck models [306056]. By …
Bristol-Myers Squibb (BMS) is developing entecavir, a viral replication inhibitor, for the potential treatment of hepatitis B virus ( …
AIDSVAX. VaxGen.
Billich A. Billich A. Curr Opin Investig Drugs. 2001 Sep;2(9):1203-8. Curr Opin Investig Drugs. 2001. PMID: 11717805 Review.
AIDSVAX, a bivalent vaccine consisting of a preparation of recombinant gp120 from two types of HIV, is being developed by VaxGen for the potential prevention of HIV infection [274573]. ...In August 1998, a collaborative research agreement was signed with the …
AIDSVAX, a bivalent vaccine consisting of a preparation of recombinant gp120 from two types of HIV, is being developed by VaxG …
The non-immunosuppressive cyclosporin A analogue SDZ NIM 811 inhibits cyclophilin A incorporation into virions and virus replication in human immunodeficiency virus type 1-infected primary and growth-arrested T cells.
Mlynar E, Bevec D, Billich A, Rosenwirth B, Steinkasserer A. Mlynar E, et al. J Gen Virol. 1997 Apr;78 ( Pt 4):825-35. doi: 10.1099/0022-1317-78-4-825. J Gen Virol. 1997. PMID: 9129655
Binding to cyclophilin A, the intracellular receptor for cyclosporins, is a prerequisite for HIV-1 inhibition by cyclosporins. ...Significant amounts of cyclophilin A were found to be associated with virus particles propagated in primary T cells. SDZ NIM 811 …
Binding to cyclophilin A, the intracellular receptor for cyclosporins, is a prerequisite for HIV-1 inhibition by cyclosporins. …
FTY720, an immunomodulatory sphingolipid mimetic: translation of a novel mechanism into clinical benefit in multiple sclerosis.
Baumruker T, Billich A, Brinkmann V. Baumruker T, et al. Expert Opin Investig Drugs. 2007 Mar;16(3):283-9. doi: 10.1517/13543784.16.3.283. Expert Opin Investig Drugs. 2007. PMID: 17302523 Review.
FTY720 (fingolimod; 2-amino-2[2-(4-octylphenyl)ethyl]-1,3-propanediol, Novartis) is the prototype of a new generation of immunomodulators. ...Animal studies suggest that this novel mechanism translates into effective treatments for several autoimmune diseases and a
FTY720 (fingolimod; 2-amino-2[2-(4-octylphenyl)ethyl]-1,3-propanediol, Novartis) is the prototype of a new generation of immunomodula …
AIDSVAX VaxGen.
Billich A. Billich A. Curr Opin Investig Drugs. 2004 Feb;5(2):214-21. Curr Opin Investig Drugs. 2004. PMID: 15043397 Review.
AIDSVAX, a bivalent vaccine consisting of a preparation of recombinant gp120 from two types of HIV, is being developed by VaxGen for the potential prevention of HIV infection. ...
AIDSVAX, a bivalent vaccine consisting of a preparation of recombinant gp120 from two types of HIV, is being developed by VaxG …
119 results
Jump to page
Feedback